All In Biotech

NDA 210566 · Mayne Pharma

Lexette

Halobetasol Propionate · Topical

Discontinued

Last checked: Nov 20, 2026Latest source record: Jul 19, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

May 24, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

28

6 Phase 3, 0 recruiting

FAERS reports

918

259 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 18, 2021 Supplement 3 · Efficacy LetterLabel
  • May 24, 2018 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination LabelLetterReview
1 products under this application
  • LEXETTE · HALOBETASOL PROPIONATE 0.05% · AEROSOL, FOAM, TOPICAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Halobetasol Propionate" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective198
  • psoriasis135
  • pruritus91
  • product use in unapproved indication73
  • rash65
  • dry skin50
  • arthralgia49
  • dermatitis atopic49
  • skin exfoliation45
  • pain44
  • product dose omission issue38
  • therapeutic product effect incomplete38

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20053
20062
20103
20116
20129
201314
201411
201526
201636
201727
201831
201946
202063
202172
2022140
2023233
202474
202567
202655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 41 on PubMed

Sponsor: Mayne Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.